Insurance-Driven Switching and Real-World Treatment Outcomes of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study

Journal article

Peer reviewed

Yumeng T Engelking and Ali Jabbari

Journal of the American Academy of Dermatology, Vol.95(1), pp.218-221

07/2026

DOI: 10.1016/j.jaad.2026.02.115

PMCID: PMC13288419

PMID: 41791515

View Online

no abstract | brief report

Treatment switching

Tofacitinib

Efficacy

JAK inhibitor

Hair regrowth

SALT score

Insurance authorization

Ritlecitinib

Treatment duration

Baricitinib

Alopecia areata

Title: Subtitle: Insurance-Driven Switching and Real-World Treatment Outcomes of Janus Kinase Inhibitors in Alopecia Areata: A Retrospective Cohort Study
Creators: Yumeng T Engelking - University of Iowa
Ali Jabbari - University of Iowa
Resource Type: Journal article
Publication Details: Journal of the American Academy of Dermatology, Vol.95(1), pp.218-221
DOI: 10.1016/j.jaad.2026.02.115
PMID: 41791515
PMCID: PMC13288419
NLM abbreviation: J Am Acad Dermatol
ISSN: 1097-6787
eISSN: 1097-6787
Publisher: Elsevier
Grant note: U.S. Department of Veterans Affairs: BX004907 National Institutes of Health: R01AR077194
This work was supported by salary and grant to DrJabbari from the U.S. Department of Veterans Affairs (BX004907) and the National Institutes of Health (R01AR077194). No additional external funding was directly awarded to the student author.
Language: English
Electronic publication date: 03/04/2026
Date published: 07/2026
Academic Unit: Dermatology
Record Identifier: 9985141991702771

6 Record Views